AbbVie Inc. (ABBV)
3 Dividend Stocks That Are Screaming Buys in November
Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends.
AbbVie: Upgrading To 'Strong Buy' After Pullback
In recent days, financial market participants have remained pessimistic about AbbVie's prospects, mainly due to the data on clinical outcomes related to emraclidine. However, I believe Mr. Market overreacted to this news, given the increase in dividend payments and the full-year non-GAAP EPS. AbbVie continues to be a leader in the global immunology market, thanks in part to the strong performance of its two stars, Skyrizi and Rinvoq.
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
The European Commission approves ABBV's Elahere for the treatment of platinum-resistant ovarian cancer.
High-Conviction Investing - 4 Of The Best Dividend Stocks Money Can Buy
The current market presents a complex mix of opportunities and risks, influenced by the Trump presidency, Fed policies, and elevated valuations. These factors require careful stock selection. I am focusing on sectors with strong recovery potential and long-term tailwinds, such as transportation and defense, while considering valuation and growth potential. My picks include high-quality, dividend-paying stocks positioned for growth, pricing power, and resilience, making them ideal investments for a volatile market.
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
Can This Dividend King Ever Hit $400 After This Major Fail?
Pharmaceutical giant AbbVie (NYSE:ABBV) has suffered a meltdown over the past week, with shares losing 15% of their value.
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
The drugmaker has convincingly laid to rest the biggest threat to its top line.
Final Trades: Bitcoin, Abbvie and Baker Hughes
The Investment Committee reveals their final trades for today.
2 Dividend Stocks to Buy Hand Over Fist in November
These companies have solid businesses and excellent dividend growth track records.
